{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:16:26Z","timestamp":1772208986097,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T00:00:00Z","timestamp":1435881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10157-015-1139-6","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T04:41:35Z","timestamp":1435812095000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome"],"prefix":"10.1007","volume":"20","author":[{"given":"Yoei","family":"Miyabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Iwabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,3]]},"reference":[{"key":"1139_CR1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ki.1986.130","volume":"29","author":"F Nolasco","year":"1986","unstructured":"Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset nephritic syndrome: a long-term follow-up. Kidney Int. 1986;29:1215\u201323.","journal-title":"Kidney Int"},{"key":"1139_CR2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000167603","volume":"8","author":"S Korbet","year":"1988","unstructured":"Korbet S, Schwartz MM, Lewis EJ. Minimal-change glomerulopathy of adulthood. Am J Nephrol. 1988;8:291\u20137.","journal-title":"Am J Nephrol"},{"key":"1139_CR3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2796.1995.tb00868.x","volume":"237","author":"R Eastell","year":"1995","unstructured":"Eastell R. Management of corticosteroid-induced osteoporosis. UK consensus group meeting on osteoporosis. J Intern Med. 1995;237:439\u201347.","journal-title":"J Intern Med"},{"key":"1139_CR4","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1359\/jbmr.2000.15.9.1645","volume":"15","author":"PN Sambrook","year":"2000","unstructured":"Sambrook PN. Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res. 2000;15:1645\u20139.","journal-title":"J Bone Miner Res"},{"key":"1139_CR5","first-page":"199","volume":"14","author":"PS Gulko","year":"1996","unstructured":"Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol. 1996;14:199\u2013206.","journal-title":"Clin Exp Rheumatol"},{"key":"1139_CR6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/rheumatology\/39.4.389","volume":"39","author":"D Jardinet","year":"2000","unstructured":"Jardinet D, Lef\u00e8bvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford). 2000;39:389\u201392.","journal-title":"Rheumatology (Oxford)"},{"key":"1139_CR7","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: amulticentric series of 22 cases. Pediatr Nephrol. 2008;23:1269\u201379.","journal-title":"Pediatr Nephrol"},{"key":"1139_CR8","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1139_CR9","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/ndt\/gfm128","volume":"22","author":"JM Hofstra","year":"2007","unstructured":"Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transpl. 2007;22:2100\u20132.","journal-title":"Nephrol Dial Transpl"},{"key":"1139_CR10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1053\/j.ajkd.2006.10.015","volume":"49","author":"H Fran\u00e7ois","year":"2007","unstructured":"Fran\u00e7ois H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis. 2007;49:158\u201361.","journal-title":"Am J Kidney Dis"},{"key":"1139_CR11","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1056\/NEJMc063706","volume":"356","author":"A Bagga","year":"2007","unstructured":"Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007;356:2751\u20132.","journal-title":"N Engl J Med"},{"key":"1139_CR12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc AL, Macher MA, Loirat C, Gu\u00e9rin V, Watier H, Peuchmaur M, Baudouin V, Desch\u00eanes G. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109\u201315.","journal-title":"Pediatr Nephrol"},{"key":"1139_CR13","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, D\u00f6tsch J. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transpl. 2012;27:1910\u20135.","journal-title":"Nephrol Dial Transpl"},{"key":"1139_CR14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","volume":"25","author":"S Fujinaga","year":"2010","unstructured":"Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25:539\u201344.","journal-title":"Pediatr Nephrol"},{"key":"1139_CR15","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM. Short-term effects of rituximab in children with steroid- and calcineurindependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:1308\u201315.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1139_CR16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet"},{"key":"1139_CR17","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","volume":"28","author":"T Takei","year":"2013","unstructured":"Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, Tsuruta Y, Ochi A, Amemiya N, Mochizuki T, Uchida K, Tsuchiya K, Nitta K. Effect of single-dose rituximab on steroid-dependent minimal change nephrotic syndrome in adults. Nephrol Dial Transpl. 2013;28:1225\u201332.","journal-title":"Nephrol Dial Transpl"},{"key":"1139_CR18","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1097\/MD.0000000000000300","volume":"93","author":"Y Iwabuchi","year":"2014","unstructured":"Iwabuchi Y, Takei T, Moriyama T, Itabashi M, Nitta K. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore). 2014;93:e300.","journal-title":"Medicine (Baltimore)."},{"key":"1139_CR19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","volume":"83","author":"H Munyentwali","year":"2013","unstructured":"Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Desch\u00eanes G, Ronco PM, Plaisier EM, Dahan KY. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83:511\u20136.","journal-title":"Kidney Int"},{"key":"1139_CR20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u00e0 M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G, Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"1139_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5414\/CN107187","volume":"77","author":"K Miyazaki","year":"2012","unstructured":"Miyazaki K, Sugimoto K, Tsuji S, Iharada A, Fujita S, Yanagida H, Sakata N, Okada M, Kaneko K, Takemura T. GSTT1 gene abnormality in minimal change nephrotic syndrome with elevated serum immunoglobulin E. Clin Nephrol. 2012;77:261\u20136.","journal-title":"Clin Nephrol"},{"key":"1139_CR22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwars JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613\u201320.","journal-title":"Arthritis Rheum"},{"key":"1139_CR23","doi-asserted-by":"crossref","unstructured":"Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3: 85ra46.","DOI":"10.1126\/scitranslmed.3002231"},{"key":"1139_CR24","author":"D Hahn","year":"2015","unstructured":"Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015;. doi: 10.1002\/14651858 .","journal-title":"Cochrane Database Syst Rev"},{"key":"1139_CR25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2169\/internalmedicine.49.3707","volume":"49","author":"T Takei","year":"2010","unstructured":"Takei T, Itabashi M, Tsukada M, Sugiura H, Moriyama T, Kojima C, Shiohira S, Shimizu A, Karasawa K, Amemiya N, Kawanishi K, Ogawa T, Uchida K, Tsuchiya K, Nitta K. Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome. Intern Med. 2010;49:2065\u201370.","journal-title":"Intern Med"},{"key":"1139_CR26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, D\u00f6rner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P, Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909\u201320.","journal-title":"Ann Rheum Dis"},{"key":"1139_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10067-012-2094-1","volume":"32","author":"M Can","year":"2013","unstructured":"Can M, Alibaz-\u00d6ner F, Y\u0131lmaz-\u00d6ner S, Atag\u00fcnd\u00fcz P, \u0130nan\u00e7 N, Direskeneli H. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience. Clin Rheumatol. 2013;32:87\u201390.","journal-title":"Clin Rheumatol"},{"key":"1139_CR28","author":"J Patel","year":"2013","unstructured":"Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Rapid infusion rituximab for maintenance therapy: is it feasible? Leuk Res Treat. 2013;. doi: 10.1155\/2013\/629283 .","journal-title":"Leuk Res Treat."},{"key":"1139_CR29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456\u201373.","journal-title":"Cancer Treat Rev"},{"key":"1139_CR30","doi-asserted-by":"crossref","unstructured":"Shirakawa H, Ishida H, Shimizu T, Omoto K, Iida S, Toki D, Tanabe K. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transpl. 2011; 25: 878\u201384.","DOI":"10.1111\/j.1399-0012.2010.01384.x"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1139-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-015-1139-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1139-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:44:45Z","timestamp":1559126685000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-015-1139-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1007\/s10157-015-1139-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,3]]}}}